Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

De-Novo Drug Design of Shorter Chain Peptide as Antitubercular Agents

Author(s): Priyanka Sharma, K. Nagarajan and Parul Grover

Tuberculosis remains a deadly disease throughout worldwide and the emergence of Multidrug resistance makes us an urgent need to find a therapeutic lead using bio-friendly shorter chain peptides. 200 peptide templates (di, tri,tetra & penta peptide 50 each) were selected for rational drug design approach viz., Lipinski filters, Boman index, molinspiration & Swiss dock procedure in which 1 amino acid was mandatory chosen from past literature survey & the rest of combinations by trite and trial basis. Among the results obtained from Lipinski only 13 peptides, namely (Try-Asp, Ile-Arg, Leu-Arg, Glu-Arg, Asp-Glu, Asp-Pro-Phe, Gly-Ala-Asp, Met-Asp-Val, Gly-Ala- Leu-Asp, Pro-Gly-Asp-Ala, Gly-Ala-Leu-Arg-Ser, & Ala-Cys-Gly-Ser-Asp are predicted to be best outcome leads against tuberculosis. Further among 13 leads subjected to Boman index calculations & molecular properties of molinspiration, we found that 9 leads were considered as better targets (rejected leads : Pro-Gly-Asp-Ala, Gly-Ala- Asp, Gly-Ala-Leu-Arg-Ser, Ala-Cys-Gly-Ser-Asp for both HGPRT enzyme and TLR-2 receptor. Among the 9 leads subjected to docking against Hypoxanthine Guanine Phospho Ribosyl Transferase enzyme & Toll like receptor 2, we found that dipeptide Glu-Arg (D-E) is considered to be the most potent therapeutic lead against HGPRT enzyme with its full fitness energy as -395546 k.cal/mols and the dipeptide Asp-Glu (D-E) was found to be the most potent therapeutic lead against TLR-2 receptor for TB with its full fitness energy as -978870 k.ca/mol respectively. Further these dipeptide lead can be explored to test preclinical efficacy & comparison of therapeutic potency will be validated through structure based drug design in near future.


PDF

FIND ARTICLES
SCImago Journal & Country Rank
Recommended Conferences
bornova escort karşıyaka escort osmangazi escort buca escort anne porno fetiş porno anal porno bartın escort burdur escort eskişehir escort escort izmir bursa escort porno escort bayan